165 related articles for article (PubMed ID: 38258341)
21. Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers.
Abu-Hejleh T; Mezhir JJ; Goodheart MJ; Halfdanarson TR
Curr Oncol Rep; 2012 Aug; 14(4):277-84. PubMed ID: 22532266
[TBL] [Abstract][Full Text] [Related]
22. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis.
Hapani S; Chu D; Wu S
Lancet Oncol; 2009 Jun; 10(6):559-68. PubMed ID: 19482548
[TBL] [Abstract][Full Text] [Related]
23. Clinical outcomes and factors related to colonic perforations in patients receiving self-expandable metal stent insertion for malignant colorectal obstruction.
Lee YJ; Yoon JY; Park JJ; Park SJ; Kim JH; Youn YH; Kim TI; Park H; Kim WH; Cheon JH
Gastrointest Endosc; 2018 Jun; 87(6):1548-1557.e1. PubMed ID: 29452077
[TBL] [Abstract][Full Text] [Related]
24. Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial.
Romera A; Peredpaya S; Shparyk Y; Bondarenko I; Mendonça Bariani G; Abdalla KC; Roca E; Franke F; Melo Cruz F; Ramesh A; Ostwal V; Shah P; Rahuman SA; Paravisini A; Huerga C; Del Campo García A; Millán S
Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):845-855. PubMed ID: 30262136
[TBL] [Abstract][Full Text] [Related]
25. Bevacizumab safety in Japanese patients with colorectal cancer.
Hatake K; Doi T; Uetake H; Takahashi Y; Ishihara Y; Shirao K
Jpn J Clin Oncol; 2016 Mar; 46(3):234-40. PubMed ID: 26774113
[TBL] [Abstract][Full Text] [Related]
26. Feasibility of surgery after systemic treatment with the humanized recombinant antibody bevacizumab in heavily pretreated patients with advanced epithelial ovarian cancer.
Sehouli J; Papanikolaou G; Braicu EI; Pietzner K; Neuhaus P; Fotopoulou C
Ann Surg Oncol; 2012 Apr; 19(4):1326-33. PubMed ID: 22090022
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of metal stents for malignant colonic obstruction in patients treated with bevacizumab.
Lee JH; Emelogu I; Kukreja K; Ali FS; Nogueras-Gonzalez G; Lum P; Coronel E; Ross W; Raju GS; Lynch P; Thirumurthi S; Stroehlein J; Wang Y; You YN; Weston B
Gastrointest Endosc; 2019 Jul; 90(1):116-124. PubMed ID: 30797835
[TBL] [Abstract][Full Text] [Related]
28. [A bowel perforation with metallic stent placement for advanced rectal cancer during bevacizumab-based chemotherapy].
Yoshinami T; Ichiba M; Hayashi S; Yamamoto K; Shibuya M; Higashimoto Y
Nihon Shokakibyo Gakkai Zasshi; 2010 Apr; 107(4):625-31. PubMed ID: 20379097
[TBL] [Abstract][Full Text] [Related]
29. [Bowel perforation associated with bevacizumab therapy in recurrent ovarian cancers without bowel obstruction or bowel involvement].
Takano M; Kikuchi Y; Kato M; Yoshikawa T; Kita T
Gan To Kagaku Ryoho; 2008 Nov; 35(11):1981-4. PubMed ID: 19011357
[TBL] [Abstract][Full Text] [Related]
30. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.
Kozloff M; Yood MU; Berlin J; Flynn PJ; Kabbinavar FF; Purdie DM; Ashby MA; Dong W; Sugrue MM; Grothey A;
Oncologist; 2009 Sep; 14(9):862-70. PubMed ID: 19726453
[TBL] [Abstract][Full Text] [Related]
31. Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer.
Redondo A; Colombo N; McCormack M; Dreosti L; Nogueira-Rodrigues A; Scambia G; Lorusso D; Joly F; Schenker M; Ruff P; Estevez-Diz M; Irahara N; Donica M; Gonzalez-Martín A
Gynecol Oncol; 2020 Oct; 159(1):142-149. PubMed ID: 32763109
[TBL] [Abstract][Full Text] [Related]
32. Gastrointestinal Perforation With an Intraluminal Stent and Bevacizumab use in Advanced Metastatic Colorectal Cancer.
Akeel N; Toonsi WA
Cureus; 2021 Jan; 13(1):e12831. PubMed ID: 33628692
[TBL] [Abstract][Full Text] [Related]
33. Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation.
Tol J; Cats A; Mol L; Koopman M; Bos MM; van der Hoeven JJ; Antonini NF; van Krieken JH; Punt CJ
Invest New Drugs; 2008 Aug; 26(4):393-7. PubMed ID: 18335169
[TBL] [Abstract][Full Text] [Related]
34. Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer.
Akun E; Okutur K; Seber S; Korkmaz T; Aydin K; Bozkurt M; Namal E; Hasbal B; Tecimer C; Demir G
J BUON; 2012; 17(4):669-76. PubMed ID: 23335523
[TBL] [Abstract][Full Text] [Related]
35. Clinical predictors of bevacizumab-associated gastrointestinal perforation.
Tanyi JL; McCann G; Hagemann AR; Coukos G; Rubin SC; Liao JB; Chu CS
Gynecol Oncol; 2011 Mar; 120(3):464-9. PubMed ID: 21168199
[TBL] [Abstract][Full Text] [Related]
36. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Cremolini C; Antoniotti C; Rossini D; Lonardi S; Loupakis F; Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Santini D; Passardi A; Marmorino F; Grande R; Aprile G; Zaniboni A; Murgioni S; Granetto C; Buonadonna A; Moretto R; Corallo S; Cordio S; Antonuzzo L; Tomasello G; Masi G; Ronzoni M; Di Donato S; Carlomagno C; Clavarezza M; Ritorto G; Mambrini A; Roselli M; Cupini S; Mammoliti S; Fenocchio E; Corgna E; Zagonel V; Fontanini G; Ugolini C; Boni L; Falcone A;
Lancet Oncol; 2020 Apr; 21(4):497-507. PubMed ID: 32164906
[TBL] [Abstract][Full Text] [Related]
37. Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.
Sogabe S; Komatsu Y; Yuki S; Kusumi T; Hatanaka K; Nakamura M; Kato T; Miyagishima T; Hosokawa A; Iwanaga I; Sakata Y; Asaka M
Jpn J Clin Oncol; 2011 Apr; 41(4):490-7. PubMed ID: 21303790
[TBL] [Abstract][Full Text] [Related]
38. [Prognostic analysis of 443 cases of stage II colorectal cancer and the value of adjuvant chemotherapy].
Zhou ZG; Pan ZZ; Wan DS; Li LR; Wu XJ; Ding PR; Lin JZ; Peng ZH
Ai Zheng; 2009 Sep; 28(9):908-12. PubMed ID: 19728905
[TBL] [Abstract][Full Text] [Related]
39. A case of HCC successfully treated with infliximab-steroid sequential therapy for small bowel perforation due to atezolizumab/bevacizumab combination therapy.
Hagiwara S; Komeda Y; Nishida N; Yoshida A; Kudo M
Cancer Rep (Hoboken); 2022 Nov; 5(11):e1721. PubMed ID: 36224043
[TBL] [Abstract][Full Text] [Related]
40. "Spontaneous," delayed colon and rectal anastomotic complications associated with bevacizumab therapy.
August DA; Serrano D; Poplin E
J Surg Oncol; 2008 Feb; 97(2):180-5. PubMed ID: 18095268
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
